Bringing CAR T cell therapy trials to underserved populations

Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma

(2022) Daanish Hoda et al.   Future Oncology

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms

(2022) Samer Al Hadidi et al.   JAMA Network Open

Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma

(2020) Ajeet Gajra et al.   Immunotherapy

Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data

(2020) Gurbakhash Kaur et al.   Clinical Lymphoma Myeloma & Leukemia

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

(2019) Jonathan M. Loree et al.   JAMA Oncology

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE